Home » Newsletters » BioWorld Science

BioWorld Science

April 18, 2001

View Archived Issues

Antisoma and BioInvent sign manufacturing agreement for muBC-1

MediChem and Signal use structural proteomics technologies to develop novel CNS drugs

Schering-Plough seeks FDA approval of broader Clarinex indication; first launches in E.U.

Progenics reports on progress during 2000

Genome of major organism responsible for acne decoded

Pivotal trial of Neotrofin for Alzheimer's disease begins enrolling patients

Src kinase inhibitors with antitumor activity discovered at Wyeth-Ayerst

AACR presentations describe design and biological activity of new CDK inhibitor NU-6102

Axonyx provides summary of 2000 highlights and goals for 2001

Korean research suggests potential in HPV-associated cervical cancer for new arsenic compound

New phase Ib trial for the anticancer agent PI-88 to begin in Taiwan

FDA issues approvable letter for Celebrex revised labeling

Highly potent and selective azetidinone-based tryptase inhibitors pursued at BMS

MGI Pharma begins phase II trial of irofulven in hormone-refractory prostate cancer

Tranilast presented at recent scientific meeting as candidate for oligozoospermia

Advisory committee review of Xyrem rescheduled

Paxil approved for generalized anxiety disorder

GPI-0100 proves highly effective as an HSV-1 vaccine adjuvant

Cinnamic acid nitriles and their use in BPH described by Schwabe

Hypolipidemic compounds reported by Aventis in recent patent

New Neurogen compounds bind to the GABA-A receptor benzodiazepine site

Antiapoptotic substituted alpha-hydroxy acids identified at Cytovia

Delta opioid receptor agonists and their use reported by Pfizer

Hydroxamic acid-based compounds described by American Cyanamid as TNF-alpha/MMP inhibitors

Pyrimidine purinoceptor antagonists emerge from AstraZeneca R&D

Dual mechanism of action discovered for BRI-2999, an antiviral dendrimer

BCH-13520: selection of HIV-1 variants with low-level resistance

Preclinical results for fidarestat discussed at diabetes meeting in Kyoto

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 26, 2026.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026